Posts for Ticker ‘DNDN’

Top Day Trader Alerts (CIT, DNDN, F, HGSI, MOT)

This is a strange morning for day trader alerts.  There are not dozens and dozens of stocks in the big news, but those that are moving are moving big.  We have links through on each stock over at VSInvestor.com for more data and analysis on price and volume:

CIT Group Inc. (NYSE: CIT) is actually very thin volume as no NYSE trades are seen, but it is down by almost half on its bankruptcy filing.

Dendreon Corp. (NASDAQ: DNDN) is trading over 5% higher after filing for PROVENGE approval with the FDA.

Ford Motor Co. (NYSE: F) is trading up about 7% this morning on high volume.  It actually made money.

Human Genome Sciences, Inc. (NASDAQ: HGSI) is trading up over 30% at multi-year highs on its positive lupus study data at the higher dose.

Motorola Inc. (NYSE: MOT) is running rather well today.  The troubled phone and communications maker is up about 5% on an analyst upgrade and on a report in Barron’s.

You can join our open email distribution list to get updates on top analyst upgrades and downgrades, top day trader alerts, IPO’s, secondary offerings, Warren Buffett and other guru activity, M&A and more.

JON C. OGG

Posted on: November 2, 2009 – 9:57 am in Pre-Market Activity, Trading Alert, , , , ,

Media Digest 10/13/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters: The healthcare plan is about to take a step forward in Congress.

Reuters:   The debt swap at CIT (NYSE:CIT) is in trouble and could cause bankruptcy.

Reuters:   Summers says Obama policies saved economy. Read More »

Posted on: October 13, 2009 – 3:58 am in Press Digest, , , , , , , , , , , ,

Top Day Trader Alerts (BDK, DRIV, DNDN, DEPO, KBH, ONXX, V)

These are this morning’s top day trader and active alert stocks moving on volume.  We have provided links through to each stock with more detailed analysis and data at VSInvestor.com:

Black & Decker (NYSE: BDK) is running on significantly higher guidance.

Digital River, Inc. (NASDAQ: DRIV) is one of the biggest losers after Symantec is terminating a contract.

Dendreon Corporation (NASDAQ: DNDN) is surging over 5% on new solid board member additions to help it transition.

DepoMed, Inc. (NASDAQ: DEPO) is down over 30% after missing some hot flash trial endpoints.

KB Home (NYSE: KBH) is being hit by 5% on an SEC inquiry disclose.

ONYX Pharmaceuticals, Inc. (NASDAQ: ONXX) is trading up despite it acquiring a private company.

Visa Inc. (NYSE: V) is set to challenge 52-week highs on an upgrade.

You can join our open email distribution list to get updates each morning on analyst upgrades and downgrades, top day trader alerts, IPO’s and secondary offerings, Warren Buffett and other guru activity, M&A and more.

JON C. OGG

Posted on: October 12, 2009 – 8:57 am in Pre-Market Activity, Trading Alert, , , , , , ,

Top Analyst Upgrades (BCSI, CVD, TRAK, DNDN, DISH, GYMB, HPQ, M, BTU, PETM, X)

These are this Tuesday morning’s top pre-market analyst upgrades and positive research calls seen from Wall Street:

Blue Coat Systems (BCSI) started as Buy at BofA/Merrill.
Covance (CVD) upgraded to Buy at Jefferies.
DealerTrack Holdings (TRAK) upgraded to Outperform at Cowen.
Dendreon (DNDN) Started as Outperform at Leerink Swann.
DISH Network (DISH) upgraded to Outperform at Wells Fargo.
Gymboree (GYMB) upgraded to Outperform at FBR Capital.
Hewlett-Packard (HPQ) upgraded to Outperform at Credit Suisse.
Macy’s (M) upgraded to Buy at Citigroup.
Peabody Energy (BTU) upgraded to Buy at Citigroup.
Petsmart (PETM) Started as Overweight at Thomas Weisel.
US Steel (X) upgraded to Neutral at BofA/Merrill.

You can join our open email distribution list which goes out several times per week for top analyst upgrades and downgrades, top day trader alerts, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG

Posted on: September 22, 2009 – 8:17 am in Analyst Calls, , , , , , , , , , ,

Top Day Trader Alerts (BBY, BCRX, C, DNDN, ING, LXRX, YHOO)

These are this morning’s top pre-market day trader alert stocks.  We have more color and more detail on price and volume analysis linked through to each at VSInvestor.com:

Best Buy Co. (NYSE: BBY) is holding up better than many might guess considering how much it has run up. This is after light earnings.

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is fairly close to 52-week highs after signing three partnerships for Peramivir for influenza outside the U.S.

Citigroup Inc. (NYSE: C) is down but only marginally on reports of a ‘possible’ stake sale by The U.S. Government.

Dendreon Corp. (NASDAQ: (DNDN) is giving back a portion of yesterday’s gains on merger rumors.

ING Group (NYSE: ING) will be an active ADR today after the EU may block a settlement.

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is surging as a top bio-winner after moving to Phase 2 clinical trial of LX4211 in patients with type 2 diabetes.

Yahoo! Inc. (NASDAQ: YHOO) is soaring to highs not seen since July on yet another upgrade.

You can join our open email distribution list which goes out several times per week for top day trader alerts, top analyst upgrades and downgrades, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG
September 15, 2009

Posted on: September 15, 2009 – 8:57 am in After-Hours Activity, Pre-Market Activity, Trading Alert, , , , , , ,

Dendreon Gives Quarterly Report & Provenge Updates (DNDN)

Dendreon Corp. (NASDAQ: DNDN) has its quarterly results out, although it is via SEC Filing rather than via a press release.  We had this on deck for a report this week and a conference call was set for Tuesday at 11:30 AM EST.

Dendreon’s total operating expenses were $20.929 million and net loss after items of $126.7 million after a $105+ million warrant item.  That is not just from operations and it does include many ongoing or new items.  That comes to a loss of $1.20 EPS and revenues were listed as $25,000.00.

More importantly, the company disclosed its expansion facilities and the associated costs in Georgia and in California.  Dendreon is still expecting PROVENGE to be approved and it gave updates along those lines.

FULL DETAILS of the financial data and updates on Provenge are at BioHealthInvestor.com.

Posted on: August 10, 2009 – 1:29 pm in Biotech, Earnings,

The Unusual Suspects (MS, GENZ, SPPI, CBST, DNDN, OPXA, BRK-A, FRED, GSIC, AMAT, WMT, LEAP, PCS)

We have some very unusual developments that came late in the week that we want you to keep on your watch lists for the coming week.  We also included the big events coming down the pipe for next week.  Morgan Stanley (NYSE: MS) is of ongoing interest.  Genzyme Corp. (NASDAQ: GENZ), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Dendreon Corp. (NASDAQ: DNDN), Opexa Therapeutics, Inc. (NASDAQ: OPXA) are all of special interest this next week.  Other key issues to watch will be Berkshire Hathaway Inc. (NYSE: BRK-A), Fred’s Inc. (NASDAQ: FRED), GSI Commerce Inc. (NASDAQ: GSIC), Applied Materials Inc. (NASDAQ: AMAT), Wal-Mart Stores Inc. (NYSE: WMT), Leap Wireless (NASDAQ: LEAP), and MetroPCS (NYSE: PCS).
Read More »

Posted on: August 8, 2009 – 11:47 am in Biotech, Calendar, Earnings, Economy, Rumors, Secondary Offering, Semiconductor, Technology Companies, Wireless, , , , , , , , , , , , ,

Top 10 Analyst Upgrades & Downgrades (ACN, ASCA, KMX, DNDN, FRO, MEOH, PGR, VRSN, WAT)

These are the top ten analyst upgrades and downgrades we have seen from Wall Street early this Monday morning with more than two hours until the market opens:

  • Accenture (ACN) Raised to Positive at Susquehanna.
  • Ameristar Casinos (ASCA) Raised to Overweight at JPMorgan.
  • CarMax (KMX) Cut to Hold at Deutsche Bank.
  • Dendreon (DNDN) Raised to Hold from Sell at McAdams Wright Ragen.
  • Frontline Ltd. (FRO) Raised to Buy at Goldman Sachs.
  • Methanex (MEOH) Cut to Outperform at Raymond James.
  • Progressive (PGR) Cut to Market Perform at FBR.
  • VeriSign (VRSN) Raised to Overweight at JPMorgan.
  • Waters (WAT) Raised to Outperform at Robert W. Baird.

Jon C. Ogg
June 22, 2009

Posted on: June 22, 2009 – 6:23 am in Analyst Calls, , , , , , , , ,

Surprise Short Selling Changes (DNDN, DRYS, ETFC, FLEX, GRMN, SIRI, AMTD)

After looking through the short interest changes for the end of May.  We saw unusual gains in short selling increases in Dendreon Corporation (NASDAQ: DNDN), DryShips Inc. (NASDAQ: DRYS), E*TRADE Financial Corp. (NASDAQ: ETFC), Flextronics International (NASDAQ: FLEX), Garmin Ltd. (NASDAQ: GRMN), Sirius XM Radio Inc. (NASDAQ: SIRI), and TD Ameritrade Holding (NASDAQ: AMTD). As you will see below, we included the stocks and the short interest changes:
Read More »

Posted on: June 10, 2009 – 11:02 am in Short Interest, , , , , , ,

Analyst Projecting 50% Upside in Dendreon (DNDN)

Money Stack ImageDendreon Corporation (NASDAQ: DNDN) was started with a Buy rating and a $36.00 target at Deutsche Bank.  The call’s positive expectations are mixed near-term, but the assumption is that Provenge will become a blockbuster product in the fight against metastatic Prostate cancer. After looking through all the notes, it appears that this may be the second highest price target from all of the analysts out there.

Read More »

Posted on: June 5, 2009 – 6:39 am in Analyst Calls, Biotech, Drug companies, FDA,

ASCO Winner: Biovest May Be The Next Dendreon (BVTI, ABPIQ, DNDN)

Money Stack ImageOne of the largest percentage gainers with data released at the American Society of Clinical Oncology was none other than an OTC micro-cap company called Biovest International, Inc. (OTC: BVTI).  Technically, this is a majority owned subsidiary company of Accentia Biopharmaceuticals, Inc. (OTC: ABPIQ).  The company has nothing to do with Dendreon Corp. (NASDAQ: DNDN) in the business, but the targets of the potential products use the body’s own immune system to fight tumors strike a similar interest.  And this weekend’s data released was far better than most were expecting from a company of this size.

We also covered this one in our weekly “10 Stocks under $10″ Newsletter as one with a big win under its belt.  The percentages of success were that large.  As noted:
Read More »

Posted on: June 1, 2009 – 12:23 pm in Biotech, Drug companies, Medical, Pharmaceuticals, Trading Alert, , ,

Short Sellers Flee Tech Stocks (MSFT)(CSCO)(ORCL)(JNPR)

bearThe sharp rally in technology stocks over the past two weeks has pushed short sellers out of the market.

The short interest in Microsoft (MFST) fell 29% in the period ending May 15 to 56.5 million shares. Shares sold short in Cisco (CSCO) dropped 26% to 50.1 million. The short interest in Oracle (ORCL) plunged 26% to 37.4 million. Shares short in Juniper (JNPR) dropped 18% to 43.2 million. Read More »

Posted on: May 27, 2009 – 6:56 pm in Autos, Banking, Financial Stocks, Hardware, Internet, Short Interest, Software, Technology, , , , , , , , , , , , , ,

Dendreon Takes In More Than $200 Million in New Cash (DNDN)

Money Stack ImageDendreon Corporation (NASDAQ: DNDN) is selling stock to raise cash.  The company has announced a spot secondary offering of 10.7 million shares in a public secondary offering of common stock.  This comes on the heels of an exponential stock gain, even after insiders unloaded enough stock to secure millionaire statuses for quite some time.
Read More »

Posted on: May 8, 2009 – 8:32 am in Biotech, Secondary Offering,

Dendreon Insiders Unload Stock (DNDN)

money-stack-image1There was an interesting twist in the ongoing Dendreon Corp. (NASDAQ: DNDN) story that developed after 5:00 PM Friday.  There was a whole series of FORM 4 filings insider sales filings with the SEC.  While it is obvious that most of these were options being exercised and company stock grants, it was hard to not notice how many insiders sold stock.  If the insiders sold this many shares, it is very likely that other company employees sold as well.  This is probably not such a surprise when you have a company’s stock rise tenfold from the lows and when many employees become instant stock option millionaires.  But still, there is the hope that Dendreon will have a blockbuster drug for advanced prostate cancer after  (and if) PROVENGE is approved by the FDA at some point in 2010.  There are many who believe that Dendreon might even now be a takeover target.  Considering that, does it at least make you wonder if employees are taking this much money out of the stock?
Read More »

Posted on: May 2, 2009 – 11:54 am in Biotech, Cult Stock, Drug companies, Insider Activity,

Analysts Piling Into Dendreon (DNDN)

Dendreon Corp. (NASDAQ: DNDN) has already been all over the news with its positive PROVENGE data for the submission of an FDA application now looking likely late in 2009 with the hopes of a early-2010 to mid-2010 launch in the war against advanced prostate cancer.  So far, analysts have been stepping all over themselves to either raise their ratings and price targets.
Read More »

Posted on: April 29, 2009 – 8:01 am in Analyst Calls, Biotech,

Media Digest 4/29/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaper27According to Reuters, the days of the CEOs of Bank of America (BAC) and Citigroup (C) may be numbered.

Reuters reports that a deal has been reached to cut Chrysler’s debt but a bankruptcy is still possible.

Reuters reports that Citigroup has sought approval to pay some bonuses.

Reuters writes that Apple (AAPL) may be using the iPhone to play Verizon (VZ) off against AT&T (T) Read More »

Posted on: April 29, 2009 – 2:52 am in Autos, Banking, Biotech, Cable Companies, Economy, Financial Stocks, Management Change, Press Digest, Software, , , , , , , , , , , , , , , , , , , ,

NASDAQ Reviewing Dendreon Trading Ahead of Halt (DNDN)

Story UPDATED at 3:10 EST:

15:05:01 EST NASDAQ has reviewed the transactions under rule 11890 (b) on its own motion filing involving the security Dendreon Corp. (NASDAQ: DNDN) executed between 13:25:00 and 13:27:02 ET today and has determined that all trades will stand. This decision cannot be appealed.

In short, if you got stopped out or shaken out of or into the stock, NASDAQ is telling you “Tough Cookie!”

JON C. OGG

A call into NASDAQ Marketwatch has confirmed that the NASDAQ is looking into erroneous trading in Dendreon Corporation (NASDAQ: DNDN).  As the NASDAQ has posted:

  • NASDAQ MarketWatch is investigating potentially erroneous transactions involving the security Dendreon Corp. (DNDN) executed between 13:25:00 and 13:27:02 ET today. MarketWatch will advise with details as soon as available. Participants should review their trading activity for potentially erroneous trades and request adjudication through the Clearly Erroneous process within the applicable timeframe for filing pursuant to the rule.

JON C. OGG

Posted on: April 28, 2009 – 1:41 pm in Biotech, Trading Alert,

Dendreon Controversy Continues (DNDN)

Dendreon Corporation (NASDAQ: DNDN) was halted today at 13:27:02 ahead of the data embargo due at 2:00 PM EST.  The data for its key Phase III IMPACT study for PROVENGE as a last line of defense in advanced prostate cancer patients is out.  The company said that the median survival rate was extended by 4.1 months to 25.8 months, and the drug increased the 3-year survival rates by 38% compared to the placebo.  The company also reported that there was a 22.5% reduction in the risk of death (31.7% versus 23.0%), which is above that 22% hurdle that the company has said would be required for an FDA approval.  It also exhibited a favorable safety profile and represents the first active cellular immunotherapy for cancer to prolong survival by using the bodies own immune system against cancer.

Full study results are here, and the conference call will take place at 5:30 PM EST (4:30 PM Central Time).  After the pre-halt trading saw a rapid 45% drop and without knowing if NASDAQ is honoring trades around the halt time, there is a high chance that this stock’s volatility is going to be present for some time.

JON C. OGG

Posted on: April 28, 2009 – 1:14 pm in Biotech,

Dendreon’s 24-Hour Countdown With Options (DNDN)

Using stock options in Dendreon Corp. (NASDAQ: DNDN) shows that the expectations of major price moves  have not let up, and the company’s stock is trading up yet again ahead of the data due to be released on Tuesday at the American Urological Association in Chicago.  The data, due to post shortly before the close, could formalize the make-or-break status of PROVENGE for the treatment of advanced prostate cancer.  And therefore, the company.  This will hopefully be the first formal data after the company said that its IMPACT study of PROVENGE for advanced prostate cancer met endpoints and was consistent with prior findings.  Again, no formal details nor any formal statistics have yet been offered.  We have the baseline endpoint goal for statistical significance as being 22% and a survival benefit of roughly 4 and-a-half months.
Read More »

Posted on: April 27, 2009 – 11:30 am in Biotech, Cult Stock, Options, Trading Alert,

Top Analyst Upgrades (ANDE, CAT, CELG, CLX, DNDN)

money-stack-image45It is actually looking pretty thin out there in the land of analyst upgrades.  These are the few upgrades and positive research calls we have seen from Wall Street this Wednesday morning with about two hours until the market open:

Andersons (ANDE) Raised to Buy at Piper Jaffray.
Caterpillar (CAT) Raised to Overweight at JPMorgan.
Celgene (CELG) Raised to Outperform at Bernstein.
Clorox (CLX) Started as Outperform at RBC.
Dendreon (DNDN) Raised to Buy at Merriman Curhan Ford.

JON C. OGG

Posted on: April 22, 2009 – 6:51 am in Analyst Calls, , , , ,